Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) EBT Margin (2016 - 2025)

International Stem Cell (ISCO) has disclosed EBT Margin for 16 consecutive years, with 3.72% as the latest value for Q2 2025.

  • On a quarterly basis, EBT Margin fell 117.0% to 3.72% in Q2 2025 year-over-year; TTM through Jun 2025 was 2.61%, a 567.0% increase, with the full-year FY2024 number at 2.34%, up 795.0% from a year prior.
  • EBT Margin was 3.72% for Q2 2025 at International Stem Cell, up from 10.24% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 4.89% in Q2 2024 to a low of 36.13% in Q1 2021.
  • A 5-year average of 10.73% and a median of 8.18% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 3568bps in 2022, then tumbled -2540bps in 2023.
  • International Stem Cell's EBT Margin stood at 19.64% in 2021, then soared by 106bps to 1.15% in 2022, then crashed by -2204bps to 24.25% in 2023, then skyrocketed by 102bps to 0.49% in 2024, then skyrocketed by 658bps to 3.72% in 2025.
  • Per Business Quant, the three most recent readings for ISCO's EBT Margin are 3.72% (Q2 2025), 10.24% (Q1 2025), and 0.49% (Q4 2024).